Headline
The latest stories from AHA Today.
The Medicaid and Children’s Health Insurance Program Payment and Access Commission released its March report to Congress, which recommends automatically increasing the federal share of Medicaid expenditures during economic downturns to support increased enrollment and decreased state revenue.
On this AHA Advancing Health podcast, Esther Corpuz, CEO of Alivio Medical Center in Chicago, talks about combating the COVID-19 pandemic through testing, vaccinations and education within the community.
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response released "The Storm After the Storm: Healthcare in Texas Recovers from Severe Winter Weather.”
The Food and Drug Administration launched a dashboard that will provide weekly updates on adverse events submitted to its adverse event reporting system for COVID-19 drugs and biological products authorized for emergency use.
The Centers for Disease Control and Prevention allocated $10 billion to states and territories from the American Rescue Plan Act to support testing to screen teachers, staff and students for COVID-19 to help reopen schools.
The House voted 415-3 to approve legislation (H.R. 1799) that would extend the Paycheck Protection Program through June 30, with applications accepted through May 31.
In response to feedback from AHA and others, UnitedHealthcare will allow hospitals and other health care providers to continue to access certain claims payment data through its Optum Pay platform at no cost.
The Centers for Medicare & Medicaid Services released a request for applications for practices and payers to participate in the Primary Care First Model beginning in January 2022.
“Though many parts of the US government and society have struggled to respond to COVID, large integrated multi-hospital health systems appear to have made a decisive difference in this pandemic,” consultants Jeff Goldsmith and Ian Morrison write in the Health Affairs Blog.
Moderna announced the administration of first COVID-19 vaccine doses to participants between the ages of 6 months and 12 years old as part of a phase 2/3 clinical trial.